Dashboard
1
With a growth in Operating Profit of 24.59%, the company declared Very Positive results in Mar 26
- The company has declared positive results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at CNY 255.83 MM
- NET SALES(HY) At CNY 652.96 MM has Grown at 21.7%
- ROCE(HY) Highest at 6.18%
2
With ROE of 3.36%, it has a fair valuation with a 1.33 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,481 Million (Small Cap)
54.00
NA
0.00%
-0.07
3.36%
1.51
Revenue and Profits:
Net Sales:
353 Million
(Quarterly Results - Jun 2026)
Net Profit:
39 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.92%
0%
31.92%
6 Months
13.95%
0%
13.95%
1 Year
16.67%
0%
16.67%
2 Years
112.16%
0%
112.16%
3 Years
49.35%
0%
49.35%
4 Years
64.64%
0%
64.64%
5 Years
5.54%
0%
5.54%
Beijing Beilu Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.18%
EBIT Growth (5y)
-9.88%
EBIT to Interest (avg)
1.06
Debt to EBITDA (avg)
0.75
Net Debt to Equity (avg)
0.16
Sales to Capital Employed (avg)
0.39
Tax Ratio
17.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.57%
ROE (avg)
2.68%
Valuation key factors
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
1.83
EV to EBIT
41.30
EV to EBITDA
23.15
EV to Capital Employed
1.89
EV to Sales
3.26
PEG Ratio
0.07
Dividend Yield
NA
ROCE (Latest)
4.57%
ROE (Latest)
3.36%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
353.00
320.40
10.17%
Operating Profit (PBDIT) excl Other Income
71.90
74.80
-3.88%
Interest
3.40
3.40
Exceptional Items
-0.60
2.80
-121.43%
Consolidate Net Profit
39.00
46.20
-15.58%
Operating Profit Margin (Excl OI)
128.50%
150.70%
-2.22%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 10.17% vs -3.67% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -15.58% vs -6.10% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,197.40
977.30
22.52%
Operating Profit (PBDIT) excl Other Income
181.70
150.40
20.81%
Interest
40.10
58.50
-31.45%
Exceptional Items
53.50
-12.50
528.00%
Consolidate Net Profit
88.60
0.30
29,433.33%
Operating Profit Margin (Excl OI)
66.00%
51.50%
1.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 22.52% vs 10.25% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 29,433.33% vs 100.36% in Dec 2024
About Beijing Beilu Pharmaceutical Co., Ltd. 
Beijing Beilu Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






